These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18269342)

  • 1. Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?
    Giachini FR; Callera GE; Carneiro FS; Tostes RC; Webb RC
    Expert Opin Ther Targets; 2008 Mar; 12(3):327-39. PubMed ID: 18269342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
    Camarda V; Rizzi A; Calò G; Gendron G; Perron SI; Kostenis E; Zamboni P; Mascoli F; Regoli D
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Feb; 365(2):141-9. PubMed ID: 11819032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of urotensin II in atherosclerotic cardiovascular diseases.
    Pakala R
    Cardiovasc Revasc Med; 2008; 9(3):166-78. PubMed ID: 18606380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human urotensin II as a link between hypertension and coronary artery disease.
    Watanabe T; Kanome T; Miyazaki A; Katagiri T
    Hypertens Res; 2006 Jun; 29(6):375-87. PubMed ID: 16940699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of endothelin and endothelin receptor antagonists in renal disease.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():78-88. PubMed ID: 16919017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A vasoactive peptide: urotensin II].
    Liu GQ; Zeng ZP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):525-8. PubMed ID: 16178453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin, sex and hypertension.
    Tostes RC; Fortes ZB; Callera GE; Montezano AC; Touyz RM; Webb RC; Carvalho MH
    Clin Sci (Lond); 2008 Jan; 114(2):85-97. PubMed ID: 18062774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of urotensin II in cardiovascular and renal physiology and diseases.
    Zhu YC; Zhu YZ; Moore PK
    Br J Pharmacol; 2006 Aug; 148(7):884-901. PubMed ID: 16783414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasoactive peptides in cardiovascular (patho)physiology.
    Callera G; Tostes R; Savoia C; Muscara MN; Touyz RM
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):531-52. PubMed ID: 17489676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of endothelin-1 in human hypertension.
    Shreenivas S; Oparil S
    Clin Hemorheol Microcirc; 2007; 37(1-2):157-78. PubMed ID: 17641406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence.
    Neuhofer W; Pittrow D
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():50-67. PubMed ID: 19335747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin II evokes potent vasoconstriction in humans in vivo.
    Böhm F; Pernow J
    Br J Pharmacol; 2002 Jan; 135(1):25-7. PubMed ID: 11786476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin-1 in chronic renal failure and hypertension.
    Larivière R; Lebel M
    Can J Physiol Pharmacol; 2003 Jun; 81(6):607-21. PubMed ID: 12839272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Physiology and pathophysiology of the endothelin system in cardiovascular diseases].
    Wieczorek I; Kruse HJ; Creutzig A
    Vasa; 1997 Aug; 26(3):173-9. PubMed ID: 9381782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of urotensin II in human pathophysiology].
    Piech J; Skoczylas A
    Wiad Lek; 2008; 61(10-12):277-82. PubMed ID: 19323069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual angiotensin II and endothelin receptor antagonists.
    Palaniswamy C; Selvaraj DR; Palaniappan D
    Am J Ther; 2011 May; 18(3):e67-70. PubMed ID: 20093924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium.
    Dschietzig T; Richter C; Bartsch C; Böhme C; Heinze D; Ott F; Zartnack F; Baumann G; Stangl K
    Biochem Biophys Res Commun; 2001 Nov; 289(1):245-51. PubMed ID: 11708807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin receptor antagonists in preclinical models of pulmonary hypertension.
    Pullamsetti SS; Schermuly RT
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():3-13. PubMed ID: 19335741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasoactive peptides, their receptors and drug development.
    Kusserow H; Unger T
    Basic Clin Pharmacol Toxicol; 2004 Jan; 94(1):5-12. PubMed ID: 14725609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin--role in vascular disease.
    Abraham D; Dashwood M
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v23-4. PubMed ID: 18784133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.